VP, Medicine Development Lead HaemophiliaSobi, Basel, SwitzerlandBasel, Basel-Stadt, Switzerland
OC 01.4 - Interim analysis of joint outcomes in adult and adolescent patients with severe hemophilia A receiving efanesoctocog alfa during the phase 3 XTEND-ed long-term extension study
Saturday, June 22, 202413:45 – 14:00 ICT
OC 14.1 - Perioperative management with efanesoctocog alfa in adults, adolescents, and children with severe hemophilia A in the phase 3 XTEND clinical program
Sunday, June 23, 202409:30 – 09:45 ICT
OC 50.1 - First interim analysis of clinical outcomes in adults and adolescents with severe hemophilia A receiving efanesoctocog alfa prophylaxis in XTEND-ed, a phase 3 long-term extension study
Tuesday, June 25, 202409:30 – 09:45 ICT
